• Intended for US Healthcare Professionals Only.Important Safety Information
  • Prescribing Information
  • Important Safety Information
  • Patient Site
  • Prescribing Information
  • Important Safety Information
  • Patient Site
  • Home
  • Pharmacokinetics
  • Efficacy
  • Safety
  • Dosing
  • Switching Factor
    • IXINITY Success Stories
    • Patient Types
    • Case Studies
  • Financial Support
  • The IXperience™
  • Community Support
  • FREE Trial
  • Connect with us
logo
  • Prescribing Information
  • Important Safety Information
  • Patient Site
  • Home
  • Pharmacokinetics
  • Efficacy
  • Safety
  • Dosing
  • Switching Factor
    • IXINITY Success Stories
    • Patient Types
    • Case Studies
  • Financial Support
  • The IXperience™
  • Community Support
  • FREE Trial
  • Connect with us
  • Prescribing Information
  • Important Safety Information
  • Patient Site
  • Home
  • Pharmacokinetics
  • Efficacy
  • Safety
  • Dosing
  • Switching Factor
    • IXINITY Success Stories
    • Patient Types
    • Case Studies
  • Financial Support
  • The IXperience™
  • Community Support
  • FREE Trial
  • Connect with us

The information in this section is intended for healthcare providers in the United States. I certify that I am a healthcare provider in the United States.

Yes
No

*Median (IQR) Annualized Spontaneous Bleeding Rate (AsBR) of 0
achieved with twice-weekly prophylaxis IQR (range: 0-1.22) (N=61)1

Learn about the proven efficacy and flexible treatment options of IXINITY® »

Reference: 1. IXINITY [coagulation factor IX (recombinant)] prescribing information. Chicago, IL: Aptevo BioTherapeutics LLC; September 2020.

Sitemap

  • Homepage
  • Important Safety Information
  • Switching Factor
    • IXINITY Success Stories
    • Case Studies
    • Patient Types
  • Efficacy
  • Pharmacokinetics
  • Safety
  • Dosing
  • Financial Support
  • The IXperience™
MEDEXUS PHARMA
  • Medexus Pharma
  • Privacy Policy
  • Terms of Use
  • Site Map

Consider switching your patients to IXINITY. Call your IXperience Concierge™ to start their FREE trial. 1​-8​55​-I​X​INITY (1​-8​55​-4​94-​6​489).

Aptevo BioTherapeutics LLC, Chicago, IL 60606

IXINITY® [coagulation factor IX (recombinant)] and any and all Medexus Pharma, Inc. brand, product, service and feature names, logos, and slogans are trademarks or registered trademarks of Aptevo BioTherapeutics LLC and Medexus Pharma, Inc. in the United States and/or other countries.

©2020 Medexus Pharma, Inc.  All rights reserved. MP-IX-0300

  • Medexus Pharma
  • Privacy Policy
  • Terms of Use
  • Site Map

Consider switching your patients to IXINITY. Call your IXperience Concierge™ to start their FREE trial. 1​-8​55​-I​X​INITY (1​-8​55​-4​94-​6​489).

Aptevo BioTherapeutics LLC, Chicago, IL 60606

IXINITY® [coagulation factor IX (recombinant)] and any and all Medexus Pharma, Inc. brand, product, service and feature names, logos, and slogans are trademarks or registered trademarks of Aptevo BioTherapeutics LLC and Medexus Pharma, Inc. in the United States and/or other countries.

©2020 Medexus Pharma, Inc.  All rights reserved.  MP-IX-XXXX

MEDEXUS PHARMA